Article

[Scoring system of late effects of radiations on normal tissues: the SOMA-LENT scale].

Département d'oncologie-radiothérapie, EA 643, centre hospitalier Lyon-Sud, Pierre-Bénite, France.
Cancer/Radiothérapie (Impact Factor: 1.11). 02/1997; 1(6):622-68.
Source: PubMed

ABSTRACT Radiation tolerance of normal tissues remains the limiting factor for delivering tumoricidal dose. The late toxicity of normal tissues is the most critical element of an irradiation: somatic, functional and structural alterations occur during the actual treatment itself, but late effects manifest months to years after acute effects heal, and may progress with time. The optimal therapeutic ratio ultimately requires not only complete tumor clearance, but also minimal residual injury to surrounding vital normal tissues. The disparity between the intensity of acute and late effects and the inability to predict the eventual manifestations of late normal tissue injury has made radiation oncologists recognize the importance of careful patient follow-up. There is so far no uniform toxicity scoring system to compare several clinical studies in the absence of a "common toxicity language". This justifies the need to establish a precise evaluation system for the analysis of late effects of radiation on normal tissues. The SOMA/LENT scoring system results from an international collaboration. European Organization Treatment of Cancer (EORTC) and Radiation Therapy Oncology Group (RTOG) have created subcommittees with the aim of addressing the question of standardized toxic effects criteria. This effort appeared as a necessity to standardize and improve the data recording, to then describe and evaluate uniform toxicity at regular time intervals. The current proposed scale is not yet validated, and should be used cautiously.

4 Bookmarks
 · 
499 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Radiotherapy of lung cancer is often complexe because of several organs at risk such as lung, heart, esophagus or spinal cord. An accurate balance needs to be defined between the necessities to reach a local control and to limit the risks of toxicities for each of them. Several parameters were significantly correlated with radiation induced lung toxicities (V13, V20, 30, Mean Dose) and esophagitis (V40 to V60). However no parameters are clearly defined for heart toxicities. The large number of parameters described for lung and esophagus highlights the necessity to perform an overall analysis of the DVHs that could be possible by using Nomal Tissue Complication Probability models.
    Cancer/Radiothérapie 01/2007; 11(1):92-100. · 1.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Le but de cet article est de décrire les effets de la radiothérapie pelvienne sur la sphère gynécologique à l’exclusion des ovaires. Sont ainsi décrites les conséquences immédiates et tardives sur la vulve, le vagin et l’utérus. Les mesures préventives et les stratégies de prise en charge sont discutées. Par ailleurs, ce papier insiste sur l’importance d’une description précise des lésions et sur l’intérêt des échelles standardisées comme le glossaire et l’échelle SOMA-LENT (Subjective-Objective-Management-Analytic-Late Effects of Normal Tissues) dans l’évaluation des séquelles fonctionnelles gynécologiques de la radiothérapie. The purpose of this paper is to review the effects of radiotherapy on the female reproductive tract excluding the ovarian impact. Immediate and late effects on the vulva, vagina, cervix and uterus are described. Preventive and management strategies are discussed. In addition, this paper highlights the importance of using validated tools such as the French and Italian glossary and SOMA-LENT scales to assess more precisely the late toxicity of radiotherapy on the genital tract. Mots clésRadiothérapie pelvienne-Échelle SOMA-LENT KeywordsRadiotherapy-SOMA-LENT scale
    Pelvi-périnéologie 06/2010; 5(2):121-131. · 0.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A French prospective randomized trial comparing whole breast radiotherapy with 45 Gy in 25 fractions versus 23 Gy in four fractions demonstrated equivalent 5-year local control and survival. On the basis of this data, we offer the hypofractionated regimen to women who refuse to undergo standard radiotherapy. We report our outcomes and a cost analysis. Between 2000 and 2012, 84 patients participated in this IRB-approved study and underwent whole breast radiation to 23 Gy in four fractions. Local control and survival were analyzed using the Kaplan–Meier method. Acute toxicities and overall long-term cosmetic results were assessed. Costs were estimated from 2012 Medicare reimbursement data and compared to costs from standard courses of 25 and 16 fractions. All 84 patients are included in this report. Median age was 83 (range 42–98). Most patients had stage I (80%), hormone receptor positive (90%) breast cancer. Fifty-eight patients (69%) were treated prone and 26 (31%) supine. At a median follow-up of 3 years, one local recurrence has occurred, of ductal carcinoma in situ histology. Among the 13 patients deceased, two died of metastatic breast cancer. Five-year actuarial local control is 99%, breast cancer-specific survival is 98%, and overall survival is 79%. Toxicities were limited to grade 1 dermatitis in 32 patients (38%) and grade 2 fatigue in three (4%). Sixty-three patients (75%) reported good or excellent cosmetic outcome at their last follow-up. Collected Medicare reimbursement was $4,798 for the hypofractionated course. Compared to the projected reimbursement of standard regimens, $10,372 for 25 fractions and $8,382 for 16 fractions, it resulted in a difference of $5,574 and $3,584, respectively. At a follow-up of 3 years, this hypofractionated regimen appears to be a promising approach, primarily for elderly women who are unable to undergo longer treatment courses but have indications for whole breast radiotherapy.
    The Breast Journal 05/2014; 20(3). · 1.43 Impact Factor